There are many reading this email who, like my family, have been directly impacted by cholangiocarcinoma. For all of us, and for so many facing other rare cancers, the message was the same- no approved or effective treatments are available. With this approval, that message finally begins to change.
TCF has had a close partnership with Incyte for several years as they developed Pemazyre, and we want to thank them for their commitment to the cholangiocarcinoma community. In addition, we are grateful to all of the doctors and researchers whose tireless work contributed to the development and approval of this new therapy.
Of course, there is still a very long way to go. This drug will only be available to patients who have a FGFR2 fusion driving their cancer, which is about 15% of cholangiocarcinoma patients. But this represents a major step forward for treating cholangiocarcinoma, and we are hopeful that many more therapies will follow.
Bringing a drug to approval takes many years and requires the collaborative efforts of countless individuals, and we are proud to be a part of that community. Here’s to more good news and many more new effective treatments for rare cancers to come.
Wishing you the best of health during this difficult time,
Kristen Palma
President
